Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.…
Neumora Therapeutics (NMRA) Stock Fair Value Moves Lower After Analyst Target Cuts
Neumora Therapeutics (NASDAQ: NMRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 0.3339 USD on 20 November 2026, down 87.0% over 52 weeks. Its 52-week range is 0.3011 USD to 3.650 USD: the price is 90.9% below the high and 10.9% above the low.
Its market capitalisation is 63.01M USD.
Neumora Therapeutics reports return on equity of -228.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 32.09M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 2 March 2027.